عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Egyptian Artists Hail Decision to Name Bridge in Cairo after Adel Emam

Adel Emam is one of Egypt's best-known actors [Getty]
Adel Emam is one of Egypt's best-known actors [Getty]
TT
TT

Egyptian Artists Hail Decision to Name Bridge in Cairo after Adel Emam

Adel Emam is one of Egypt's best-known actors [Getty]
Adel Emam is one of Egypt's best-known actors [Getty]

The decision to name a bridge in the Egyptian capital after star Adel Emam, also famed as “The Leader”, was widely celebrated in the artistic circles.

Emam’s name went viral on Egypt’s social media platforms, including X, after the official page of Cairo Governorate on Facebook announced the decision. According to the announcement, the governorate’s executive council presided by the governor, approved to “name some schools and public projects after Egyptian martyrs and symbols, among them is Adel Emam, whose name will be given to the bridge near the Salah Salem intersection, eastern Cairo.”

Egyptian artists described the decision as a merited tribute to Emam, who has piled great works since his debut in the 1960s, and represented Egypt in myriads international platforms. Actress Majida Zaki said “Emam’s name is like a medal. He’s the model actor who supported and inspired a whole generation of artists.”

“My first work was with him in a series named ‘Dreams of the Flying Boy’, and people knew me in this production. Everyone loves and respects the family of Adel Emam. They are known with their compassion. Emam is the mentor and compass not only for his family, but also for the entire artistic community,” she told “Asharq Al-Awsat”.

Actress Lebleba, who partnered with Emam in many works, said that “naming a public project after him is an honor and a source of pride and happiness for all artists,” adding that “he is incomparable. He captivated his audience with a diverse range of artistic creations that continue to resonate in the hearts and minds of his fans. Emam's enduring legacy as a remarkably distinctive artist has elevated him to the status of an icon. His commitment to creativity and years devoted to the world of art have solidified his unique place in the realm of artistic brilliance, she added.

For her part, Actress Sherine described “the decision as a thoughtful gesture" adding that “honoring the name of the leader is an appreciation of art and its value. Naming cinemas and theaters after artistic symbols is an esteemed tradition that the Egyptian state is accustomed to.”

Artist Salah Abdullah said he was delighted with the decision, “a great surprise that the leader deserves.” “Paying tribute to our mentor is an honor to the entire artistic movement and an appreciation of symbols who gave a lot to the Egyptian art,” he told “Asharq Al-Awsat”.

Actress Elham Shahein applauded the tribute and described it as “a triumph for all artists.”

Hani Ramzi also commented on the decision, highlighting that it’s an appreciation of the art’s role and message. “Paying tribute to the legend Adel Emam is a tribute to every Egyptian artist and to the role of soft power,” he wrote on Facebook. Artist Khaled Sarhan also hailed the decision and addressed the leader on Facebook, saying: “Your name is a landmark in itself, master.”

Egypt's Acting Professions Syndicate and the Emam family also applauded the decision, while his brother producer Issam Emam described it as “an honor for his name and family.”

Before “the leader”, the names of many stars in Egypt were given to public facilities, including Samir Ghanem, Mahmoud Abdelaziz and Mahmoud Yassine.

Back in August, the National Festival of Egyptian Theater celebrated Adel Emam by naming its 16th edition after him as a tribute to his 60-year-old journey.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”